Fulcrum Therapeutics announced its first quarter 2025 financial results, reporting $226.6 million in cash, cash equivalents, and marketable securities as of March 31, 2025. The company reiterated its cash runway guidance, expecting existing capital to fund operating requirements into at least 2027.
Significant progress was made in the Phase 1b PIONEER trial of pociredir for sickle cell disease, with enrollment completed in the 12 mg dose cohort (n=16) and the 20 mg dose cohort initiated. Clinical data from the 12 mg dose cohort is expected in early Q3 2025, and data from the 20 mg dose cohort is anticipated by the end of 2025.
Beyond pociredir, Fulcrum achieved a $0.6 million preclinical milestone in April 2025 for its inherited aplastic anemias program, including Diamond-Blackfan anemia (DBA), under a licensing agreement with CAMP4 Therapeutics. An Investigational New Drug (IND) application for DBA is planned for submission in the fourth quarter of 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.